Literature DB >> 17906637

Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes.

Jialing Huang1, Fengxiang Wang, Elias Argyris, Keyang Chen, Zhihui Liang, Heng Tian, Wenlin Huang, Kathleen Squires, Gwen Verlinghieri, Hui Zhang.   

Abstract

The latency of human immunodeficiency virus type 1 (HIV-1) in resting primary CD4+ T cells is the major barrier for the eradication of the virus in patients on suppressive highly active antiretroviral therapy (HAART). Even with optimal HAART treatment, replication-competent HIV-1 still exists in resting primary CD4+ T cells. Multiple restriction factors that act upon various steps of the viral life cycle could contribute to viral latency. Here we show that cellular microRNAs (miRNAs) potently inhibit HIV-1 production in resting primary CD4+ T cells. We have found that the 3' ends of HIV-1 messenger RNAs are targeted by a cluster of cellular miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382, which are enriched in resting CD4+ T cells as compared to activated CD4+ T cells. Specific inhibitors of these miRNAs substantially counteracted their effects on the target mRNAs, measured either as HIV-1 protein translation in resting CD4+ T cells transfected with HIV-1 infectious clones, or as HIV-1 virus production from resting CD4+ T cells isolated from HIV-1-infected individuals on suppressive HAART. Our data indicate that cellular miRNAs are pivotal in HIV-1 latency and suggest that manipulation of cellular miRNAs could be a novel approach for purging the HIV-1 reservoir.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906637     DOI: 10.1038/nm1639

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  401 in total

1.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

Review 3.  Regulation of small RNA stability: methylation and beyond.

Authors:  Lijuan Ji; Xuemei Chen
Journal:  Cell Res       Date:  2012-03-13       Impact factor: 25.617

4.  Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes.

Authors:  Li Ye; Xu Wang; Jieliang Li; Jinping Liu; Servio H Ramirez; Jianguo Wu; Wenzhe Ho
Journal:  Innate Immun       Date:  2011-09-22       Impact factor: 2.680

5.  Evidence for miRNA expression differences of HIV-1-positive, treatment-naive patients and elite suppressors: a re-analysis.

Authors:  Kenneth W Witwer; Janice E Clements
Journal:  Blood       Date:  2012-06-28       Impact factor: 22.113

6.  MicroRNAs as new players in the genomic galaxy and disease puzzles.

Authors:  Elisa Barbarotto; Paola Secchiero; Abhijit Dasgupta; Paolo Fortina; George A Calin; Terry Hyslop
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

7.  Differential regulation of microRNA stability.

Authors:  Sophie Bail; Mavis Swerdel; Hudan Liu; Xinfu Jiao; Loyal A Goff; Ronald P Hart; Megerditch Kiledjian
Journal:  RNA       Date:  2010-03-26       Impact factor: 4.942

8.  HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs.

Authors:  J Robert Chang; Ruma Mukerjee; Asen Bagashev; Luis Del Valle; Tinatin Chabrashvili; Brian J Hawkins; Johnny J He; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

9.  Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression.

Authors:  Chinmay K Mantri; Jyoti V Mantri; Jui Pandhare; Chandravanu Dash
Journal:  Am J Pathol       Date:  2013-10-26       Impact factor: 4.307

Review 10.  MicroRNAs: history, biogenesis, and their evolving role in animal development and disease.

Authors:  M Bhaskaran; M Mohan
Journal:  Vet Pathol       Date:  2013-09-17       Impact factor: 2.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.